Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo

Radiation Research

Volumn 178, Issue 3, 2012, Pages 126-137

  Kim, Eugene Y ^a   Liu, Yanfeng ^a   Akintujoye, Oluwatoyin M ^a   Shyam, Krishnamurthy ^a   Grove, Tina A ^a,b   Sartorelli, Alan C ^a   Rockwell, Sara ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALKYLATING AGENT; KS 119; KS119W; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; HYPOXIC CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

AEROBIOSIS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; HYDRAZINES; HYDROGEN-ION CONCENTRATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; SOLUBILITY; WATER;

MUS;

EID: 84866328854     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2934.1     Document Type: Article

References (52)

1. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10:695-712. (Pubitemid 14084223)
2. Moulder JE, Rockwell S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metast Rev 1987; 5:313-41.
3. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: Past history, ongoing research, and future promise. Curr Mol Med 2009; 9:442-58.
4. Rockwell S. Oxygen delivery: Implications for the biology and therapy of solid tumors. Oncol Res 1997; 9:383-90. (Pubitemid 127825992)
5. Dewhirst MW. Failla Memorial Lecture-Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009; 172:653-65.
6. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82:699-757. (Pubitemid 44832019)
7. Fukumura D, Jain RK. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101:937-49. (Pubitemid 47040874)
8. Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC. The hypoxic tumor cell: A target for selective cancer chemotherapy. Biochem Pharmacol 1980; 29:1-8. (Pubitemid 10212788)
9. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 1988; 48:775-8. (Pubitemid 18061861)
10. Rockwell S. Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol 1992; 19:29-40.
11. Shyam K, Penketh PG, Shapiro M, Belcourt MF, Loomis RH, Rockwell S, et al. Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1, 2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J Med Chem 1999; 42:941-6.
12. Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Exp Opin Invest Drugs 2000; 9:2889-901.
13. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol 2007; 19:427-42. (Pubitemid 46995614)
14. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:437-46.
15. Overgaard J. Hypoxic modification of radiotherapy in squamous carcinoma of the head and neck-A systematic review and metaanalysis. Radiother Oncol 2011; 100:22-32.
16. Moulder JE, Dutreix J, Rockwell S, Siemann DW. Applicability of animal tumor data to cancer therapy in humans. Int J Radiat Oncol Biol Phys 1988; 14:913-27.
17. Brown JM, Diehn M, Loo BW. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 2010; 78:323-7.
18. Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 2011; 79:1188-95.
19. Carlson DJ, Yenice KM, Orton CG. Tumor hypoxia is an important mechanism of radioresistance in hypofractionated radiotherapy and must be considered in the treatment planning process. Med Phys 2011; 38:6347-50.
20. Shyam K, Penketh PG, Divo AA, Loomis RH, Patton CL, Sartorelli AC. Synthesis and evaluation of 1, 2, 2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J Med Chem 1990; 33:2259-64. (Pubitemid 20236675)
21. Seow HA, Penketh PG, Shyam K, Rockwell S, Sartorelli AC. 1, 2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy] carbonyl]hydrazine: An anticancer agent targeting hypoxic cells. Proc Natl Acad Sci USA 2005; 102:9282-7. (Pubitemid 40923555)
22. Baumann RP, Penketh PG, Seow HA, Shyam K, Sartorelli AC. Generation of oxygen deficiency in cell culture using a twoenzyme system to evaluate agents targeting hypoxic tumor cells. Radiat Res 2008; 170:651-60.
23. Baumann RP, Penketh PG, Ishiguro K, Shyam K, Zhu YL, Sartorelli AC. Reductive activation of the prodrug, 1, 2-bis(methylsulfonyl)-1-(2-chloroethyl)- 2-[[1-(4-nitrophenyl)ethoxy] carbonyl]hydrazine (KS119) selectively occurs in oxygendeficient cells and overcomes O6-alkylguanine-DNA transferase mediated KS119 tumor cell resistance. Biochem Pharmacol 2010; 79:1553-61.
24. Penketh PG, Baumann RP, Shyam K, Williamson HS, Ishiguro K, Zhu R, Eriksson ESE, Eriksson LA, Sartorelli AC. 1, 2-bis(methylsulfonyl)-1-(2- chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy] carbonyl]hydrazine (KS119): a cytotoxic prodrug with two stable conformations differing in biological and physical properties. Chem Biol Drug Des 2011; 78:513-26.
25. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem 2001; 36:577-95. (Pubitemid 32964730)
26. Ishiguro K, Shyam K, Penketh PG, Sartorelli AC. Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine. Mol Cancer Ther 2005; 4:1755-63. (Pubitemid 41685310)
27. Rockwell S. In vivo-in vitro tumor systems: New models for studying the response of tumors to therapy. Lab Anim Sci 1977; 27:831-51. (Pubitemid 8255715)
28. Rockwell S, Liu Y. Aplidin as a potential adjunct to radiation therapy: in vitro studies. Intl J Radiat Biol 2010; 86:63-70.
29. Hahn GM, Rockwell S, Kallman RF, Gordon LF, Frindel E. Repair of potentially lethal damage in vivo in solid tumor cells after x-irradiation. Cancer Res 1974; 34:351-4.
30. Ishiguro K, Zhu Y-L, Shyam K, Penketh PG, Baumann RP, Sartorelli AC. Quantitative relationship between guanine O6-alkyl lesions produced by OnriginTM and tumor resistance by O6-alkylguanine-DNA alkyltransferance. Biochem Pharmacol 2010; 80:1317-25.
31. Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, et al. Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors. Int J Radiat Biol 2012; 88:277-85.
32. Duan Q, Liu Y, Booth CJ, Rockwell S. Use of fenbendazolecontaining therapeutic diets for mice in experimental cancer therapy studies. J Am Assoc Lab Anim Sci 2012; 51:277-85.
33. Rockwell S. Tumor Cell Survival. In: Teicher B, editor. Tumor models in Cancer Research, 2nd edition. New York: Humana Press; 2010. P. 607-24.
34. Rockwell S. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Intl J Cancer 1986; 38:229-35. (Pubitemid 16043600)
35. Rockwell S, Hughes CS, Kennedy, KA. Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors. Int J Radiat Oncol Biol Phys 1991; 20:259-63.
36. Donnelly ET, Liu Y, Fatunmbi YO, Lee I, Magda D, Rockwell S. Effects of Texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 2004; 58:1570-6. (Pubitemid 38438322)
37. Collingridge DR, Rockwell S. Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas. Int J Cancer 2000; 90:256-64.
38. Rockwell S, Kelley M. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: Preliminary studies with EMT6 cells and tumors and normal tissues in mice. Radiat Oncol Invest 1998; 6:199-208. (Pubitemid 28509436)
39. Rockwell S, Kelley M, Irvin CG, Hughes CS, Porter E, Yabuki H, Fischer JJ. Modulation of tumor oxygenation and radiosensitivity by a perfluorooctylbromide emulsion. Radiother Oncol 1991; 22:92-8.
40. Keyes SR, Rockwell S, Sartorelli AC. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res 1985; 45:3642-5. (Pubitemid 15226438)
41. Steel GG. Terminology in the description of drug-radiation interactions. Intl J Radiat Oncol Biol Phys 1979; 5:1145-50. (Pubitemid 10215318)
42. Rockwell S. Toxicity of intra-arterial mitomycin C to previouslyirradiated tissues. Radiother Oncol 1986; 6:75-6. (Pubitemid 16038442)
43. Skarsgard LD, Skwarchuk MW, Vinczan A, Chaplin DJ. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells. Br J Cancer 1993; 68:681-3. (Pubitemid 23301268)
44. Rockwell S, Grindey GB. Diarlsulfonylureas and radiotherapy I. In vitro studies with N-(5-indanylsulfonyl)-N0-4(-chlorophenyl)-urea, Sulofenur. Cancer Commun 1991; 3:103-8.
45. Herman TS, Teicher BA, Collins LS. Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures. Cancer Res 1988; 48:2342-7.
46. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Intl J Radiat Oncol Biol Phys 1991; 20:287-9.
47. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006; 5:1275-9. (Pubitemid 43881320)
48. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99:1441-54.
49. Rockwell S. Hypoxia and drug resistance. In: JR Bertino. Encyclopedia of Cancer. San Diego: Academic Press; 2002. P. 461-8. (vol II).
50. Rockwell S. Combination therapy with radiation, mitomycin C, and 5-Fluorouracil in EMT6 tumors. Int J Radiat Oncol Biol Phys 1994; 28:127-33. (Pubitemid 24012864)
51. Donnelly ET, Liu Y, Rockwell S. Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of Carboplatin in EMT6 mouse mammary tumors. Exp Biol Med 2006; 231: 317-21. (Pubitemid 43334318)
52. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 2005; 90:233-9. (Pubitemid 40576836)